Smart Drug Development & Design

from Candidate to Phase I

20190404_093725_cut2.jpg

FORMULATION, MODELLING, QUALITY and STRATEGY

This event focused on key considerations for transitioning a molecule from discovery to phase 1 readiness including API and formulation development, pharmacokinetics, quality and CMC requirements, and incorporation of clinical supply services solutions to meet protocol, clinical site and patient needs.

©BioRN